Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents

Hooke, Mary C.; McCarthy, Kathleen; Taylor, Olga A.; Hockenberry, Marilyn J.

doi:10.1016/j.ejon.2014.07.015

Cited by 9 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that CDDP therapy caused urinary excretion of LC and is associated with secondary carnitine deficiency due to inhibition of carnitine reabsorption, enhancement of carnitine excretion, and inhibition of endogenous carnitine synthesis [2,4,5,6,7]. However, the observation of plasma deficiency of LC has not always been consistent among reports in patients treated with CDDP [4,8], and little information is available regarding the dynamics of LC in plasma and urine during CDDP therapy and the relations with clinical parameters in patients.…”

Section: Introductionmentioning

confidence: 68%

Dynamics of <smlcap>L</smlcap>-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

Gomi

Tanaka²,

Fukushima³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

Background and Aims: Several studies have indicated that cisplatin (cis-diamminedichloroplatinum II; CDDP) causes urinary excretion of L-carnitine (LC). However, the underlying cofactors affecting the increased urinary excretion remain unclear. The present study was performed to evaluate the dynamics of LC in plasma and urine after CDDP chemotherapy and to examine the relations with clinical parameters, such as gender, body mass index (BMI), and renal function. Methods: Twenty-two patients treated with CDDP therapy were selected. Blood and urine samples were taken from patients before starting CDDP treatment (day 0), on the next day (day 1), and on the seventh day (day 7). We measured plasma and urine concentrations of total, free, and acyl-LC, and examined the relationships with gender, age, treatment cycle, skeletal muscle mass, BMI, glomerular filtration rate, and change in creatinine concentration after CDDP administration. Results: Both urinary and plasma concentrations of 3 types of LC increased markedly on day 1 and subsequently reverted to the pre-CDDP level on day 7. There was a positive correlation between the % changes in plasma and urine LC (correlation coefficient 0.59, p = 0.003) on day 1, but no significant relations were seen in other clinical parameters. Conclusions: CDDP transiently increased plasma LC levels. The mechanism seemed to involve recruitment for marked urinary loss of LC. However, these changes in plasma and urinary LC levels were not related to clinical factors, suggesting that the dynamics of LC were independent of preexisting physical parameters.

show abstract

Section: Introductionmentioning

confidence: 68%

Dynamics of <smlcap>L</smlcap>-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

Gomi

Tanaka²,

Fukushima³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Fatigue affects Ͼ75% of patients undergoing cancer treatment and is the most commonly reported symptom of patients undergoing chemotherapy (110). Fatigue is reported to cause extreme distress due to its negative impact on the activities of daily living, reduced quality of life, and increased morbidity and mortality (51,86,117). In cancer patients, fatigue can manifest as a perceived tiredness with a lack of energy and as physical weakness with a decrease in muscle strength (41,86,110).…”

Section: Dox-induced Skeletal Muscle Toxicitymentioning

confidence: 99%

Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity

Smuder

2019

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

Doxorubicin (DOX) is a highly effective antitumor agent used for the treatment of a wide range of cancers. Unfortunately, DOX treatment results in cytotoxic side effects due to its accumulation within off-target tissues. DOX-induced cellular toxicity occurs as a result of increased oxidative damage, resulting in apoptosis and cell death. While there is no standard-of-care practice to prevent DOX-induced toxicity to healthy organs, exercise has been shown to prevent cellular dysfunction when combined with DOX chemotherapy. Endurance exercise stimulates numerous biochemical adaptations that promote a healthy phenotype in several vulnerable tissues without affecting the antineoplastic properties of DOX. Therefore, for the development of an effective strategy to combat the pathological effects of DOX, it is important to determine the appropriate exercise regimen to prescribe to cancer patients receiving DOX therapy and to understand the mechanisms responsible for exercise-induced protection against DOX toxicity to noncancer cells. This review summarizes the cytotoxic effects of DOX on the heart, skeletal muscle, liver, and kidneys and discusses the current understanding of the clinical benefits of regular physical activity and the potential mechanisms mediating the positive effects of exercise on each organ system.

show abstract

Symptom Science in Pediatric Oncology

2020

View full text Add to dashboard Cite

Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents

Cited by 9 publications

References 26 publications

Dynamics of <smlcap>L</smlcap>-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

Dynamics of <smlcap>L</smlcap>-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity

Symptom Science in Pediatric Oncology

Contact Info

Product

Resources

About